12:00 AM
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lotronex alosetron hydrochloride regulatory update

FDA's Drug Safety and Risk Management Advisory Committee will meet on July 10 to discuss the REMS with elements of safe use (ETASU) for Lotronex alosetron from GlaxoSmithKline and Nestle's Prometheus Laboratories Inc. unit. Lotronex's ETASU require healthcare providers to be specially certified and...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >